广州医科大学学报

参考文献

[1] Feldeisen T, Alexandris-Souphis C, Haymart B, et al.Anticoagulation Changes Following Major and Clinically Relevant Nonmajor Bleeding Events in Non-valvular Atrial Fibrillation Patients[J]. J Pharm Pract, 2021:8971900211064189.

[2]蔡家晟，张佑俊，曲新凯．高龄非瓣膜性心房颤动患者发生缺血性卒中的临床分析[J]．中国介入心脏病学杂志，2021,29(12):661-665.

[3] Fujimoto S. What Is the Best Anticoagulant Therapy in Acute-Phase Ischemic Stroke With Nonvalvular Atrial Fibrillation?[J].Circ J,2022,86(6):964-965.

[4] Wang JR,Du X,Dong JZ,et al.Use of oral anticoagulants and its associated factors among nonvalvular atrial fibrillation patients with new-onset acute ischemic stroke:A report from the China Atrial Fibrillation Registry study[J].Clin Cardiol,2022,45(1):60-67.

[5] D'Ancona G,Arslan F,Safak E,et al. Actual management costs of patients with non-valvular atrial fibrillation treated with percutaneous left atrial appendage closure or oral anticoagulation[J].Int J Cardiol,2022,351:61-64.

[6] Martha JW,Pranata R,Raffaelo WM,et al. Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease-A Systematic Review and Meta-Analysis[J]. Front Cardiovasc Med,2021,8:764356.

[7]周强，刘翔，吴燕子，等．利伐沙班与达比加群低剂量治疗非瓣膜性房颤患者有效性和安全性的Meta分析[J]．药学与临床研究，2021,29(6):416-420.

[8]周强，吴燕子，陶瑛瑛，等．利伐沙班与达比加群治疗老年非瓣膜性房颤有效性和安全性的Meta分析[J]．临床药物治疗杂志，2021,19(12):76-81.

[9]陈新敬，吴志勇，郭延松，等．利伐沙班在左心耳封堵术后抗凝方案中的应用[J]．广州医科大学学报，2021,49(6):64-67.

[10]洪雁，高蕊，何云燕．利伐沙班对脑梗死患者Xa因子及炎性因子的影响[J]．中国城乡企业卫生，2021,36(12):10-13.

[11] Koretsune Y, Hoshino H, Matsuo Y, et al. Comparative Safety and Effectiveness of Apixaban vs.Warfarin in Oral Anticoagulant-Na? ve Japanese Patients With NonValvular Atrial Fibrillation-A Retrospective Chart Review Study[J].Circ J,2022,86(2):213-221.

[12] Navarro-Almenzar B,Cerezo-Manchado JJ,García-Candel F. Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity[J].Int J Cardiol Heart Vasc,2021,37:100913.

[13] Coates J,Bitton E,Hendje A,et al. Clinical outcomes of dabigatran use in patients with non-valvular atrial fibrillation and weight>120? kg[J].Thromb Res,2021,208:176-180.

[14] Mocini D, Di Fusco SA, De Luca L, et al.[ANMCO Position paper:Prescription appropriateness of direct oral anticoagulants for stroke and systemic thromboembolis with non-valvular atrial fibrillation][J]. G Ital Cardiol(Rome),2021,22(12):1024-1033.

[15] Liu K,Li Y,Wu K,et al.Retrospective Study of 1255 NonAnticoagulated Patients with Nonvalvular Atrial Fibrillation to Determine the Risk of Ischemic Stroke Associated with Left Atrial Spontaneous Echo Contrast on Transesophageal Echocardiography[J]. Med Sci Monit,2021,27:e934795.

[16] Gabilondo M,Loza J,Pereda A,et al. Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants[J].Hematology,2021,26(1):277-283.

[17] Teng RL, Wang H, Sun BC, et al. Interaction between lipoprotein(a)levels and body mass index in first incident acute myocardial infarction[J]. BMC Cardiovasc Disord,2020,20(1):350.

[18] Deguchi I, Osada T, Arai N, et al. Differences in oral anticoagulant prescriptions between specialists and nonspecialists in patients with cardioembolic stroke caused by non-valvular atrial fibrillation[J].Heart Vessels,2022,37(5):867-874.

[19]孙冰，张晓东，赵勇，等．Watchman封堵器与ACP/Amulet封堵器应用于非瓣膜性房颤患者行左心耳封堵术的有效性与安全性Meta分析[J]．心脏杂志，2021,33(6):600-604.

[20]孙晓臣，刘海波，罗溶，等．利伐沙班用于非瓣膜性心房颤动伴肾功能不全患者的效果与安全性[J]．心脏杂志，2021,33(6):605-608,618.

[21]戴亨纷，郑彩云．利伐沙班用于非瓣膜性房颤治疗安全性的Meta分析[J]．海峡药学，2020,32(12):112-115.

[22]钟禹成，祝睿锐，俞坤武，等．新型口服抗凝药在治疗非瓣膜性房颤合并冠心病中的研究进展[J]．临床内科杂志，2020,37(12):830-833.

[23]赵新华．临床药师的监护指导对非瓣膜性房颤患者华法林抗凝管理的效果分析[J]．中国处方药，2020,18(12):50-52.

[24] Varona JF,Seguí-Ripoll JM,Lozano-Duran C,et al.Healthrelated quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status[J].Health Qual Life Outcomes,2020,18(1):383.

[25]梁浩，张娜，霍明艳，等．NOAC对非瓣膜性房颤经导管射频消融术后并发症发生率及房颤复发率的影响[J]．中国社区医师，2020,36(34):67-68.

[26] Zhang H, Yu M, Xia Y, et al. The differences of atrial thrombus locations and variable response to anticoagulation in nonvalvular atrial fibrillation with ventricular cardiomyopathy[J].J Arrhythm,2020,36(6):1016-1022.

[27] Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins[J].N Engl J Med,1998,339(10):659-666.

[28]吴钢，黄从新，江洪．心房颤动：消融术式和机制研究的博弈[J]．医学与哲学，2007,28(14):26-27.

[29] Esteve-Pastor MA, Rivera-Caravaca JM, Ruiz-Ortiz M,et al.A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation:effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry[J]. Expert Opin Pharmacother,2022,23(12):1457-1465.

[30] Soualmi R, Derki S, Bengalouze A, et al. PCV91CAN Disparities between Health Technology Appraisal(HTA)Decisions Result in Inequitable Access to Treatment? the Case of NOVEL ORAL Anticoagulants(NOACS)in the Prevention of Stroke in NONValvular Atrial Fibrillation(NVAF)[J]. Value in Health,2020,23(2):22-26.

[31] Gourzoulidis G,Delli E,Wammes K,et al. PCV53Cost Comparison of Low Dose Dabigatran over Other NOVEL ORAL Anticoagulants for the Treatment of Patients with NON-Valvular Atrial Fibrillation WHO HAD NOT Previously Taken an ORAL Anticoagulant in Greece[J].Value in Health,2020,23(2):55-56.

[32] Priyadarshini M, Hegde S, Wang R, et al. PCV4Stroke and Bleeding Outcomes in Europe and ASIA in Patients with Nonvalvular Atrial Fibrillation Treated with NON-Vitamin K ORAL Anticoagulants(NOACS)in Real-Word Practice[J]. Value in Health,2020,23(2):552-553.

[33]张玮艺，余萍，张潇潇，等．2016年欧洲心脏病学会心房颤动管理指南（节选）（一）[J]．中国卒中杂志，2017,12(4):355-363.

[34]斯小琴，张季谦，陈春磊，等．心肌组织死亡细胞分布对窦房结搏动信号传导功能的影响[J]．应用物理，2011,1(2):35-40.

[35] Liu L, Hong D, Ma K, et al. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China[J].J Clin Pharm Ther,2021,46(3):658-668.

[36] Yamato H, Abe K, Osumi S, et al. Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation[J].Sci Rep,2020,10(1):20144.

[37] Dhamane Amol,Di Fusco Manuela,Gutierrez Cynthia,et al. Abstract 14354:Persistence to Oral Anticoagulation Treatment in Non-valvular Atrial Fibrillation Patients in the United States[J].Circulation,2020,142(3):34-36.

[38]祁蕙，张伟霞．从临床病例分析达比加群的个体化给药方案及用药监测[J]．药物流行病学杂志，2020,29(11):772-775.

[39] Serpytis R, Navickaite A, Serpytiene E, et al. Impact of Atrial Fibrillation on Cognitive Function, Psychological Distress, Quality of Life, and Impulsiveness[J]. Am J Med,2018,131(6):703.e1-703.e5.

[40] Marott SC, Nielsen SF, Benn M, et al. Antihypertensive treatment and risk of atrial fibrillation:a nationwide study[J].Eur Heart J,2014,35(18):1205-1214.

[41]刘彦．达比加群酯与华法林在非瓣膜性房颤抗凝治疗中的应用比较[J]．中国医药指南，2019,17(36):74-75.

[42]孟云丽，李新梅，郭林林．群组管理对非瓣膜性房颤患者抗凝治疗依从性及生活质量的影响[J]．包头医学院学报，2019,35(12):58-59,111.

[43]王倩，张丽，黄俊，等．利伐沙班在高龄非瓣膜性心房颤动患者中的常用剂量及预后分析[J]．岭南心血管病杂志，2019,25(6):638-641,646.

[44]朱含．非瓣膜性房颤应用达比加群酯抗凝治疗效果及症状转归情况分析[J]．中国实用医药，2019,14(33):99-100.

[45]王亚红，肖红艳．非瓣膜性房颤老年患者华法林用药依从性及相关因素调查研究[J]．中国医药导报，2019,16(33):59-62.

[46]黄溯源，梁婷，吴建博，等．非瓣膜性心房颤动住院患者使用利伐沙班合理性评价[J]．中国新药与临床杂志，2019,38(11):699-702.

[47]宫克旭．非瓣膜性房颤的发病机制及抗凝治疗进展[J]．继续医学教育，2018,32(12):113-115.

[48]阳丽梅，陈敏，陈坚．老年非瓣膜性房颤患者利伐沙班的服药依从性分析[J]．药品评价，2018,15(24):3-6.

[49] Voudris KV,Apostolakis S,Karyofillis P,et al. Genetic diversity of the KCNE1 gene and susceptibility to postoperative atrial fibrillation[J].Am Heart J,2014,167(2):274-280.e1.

[50] Angiolillo DJ, Goodman SG, Bhatt DL, et al.Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention[J]. Circulation, 2018, 138(5):527-536.

[51]《老年人心房颤动诊治中国专家建议》写作组，中华医学会老年医学分会，中华老年医学杂志编辑委员会．老年人非瓣膜性心房颤动诊治中国专家建议（2016）[J]．中华老年医学杂志，2016,35(9):915-928.